在治疗牛皮时增强通过皮肤输送甲状腺素的电响应性纸张贴片
Elham Momtaz1, Masoud A Mehrgardi1
1Department of Chemistry, University of Isfahan 81746-73441 Isfahan, Iran.
International journal of pharmaceutics
|August 24, 2025
概括
一种基于纸的新型离子补丁有效地通过牛皮的皮肤输送甲状腺素 (MTX). 这种可穿戴设备提供了一种对患者友好的治疗方法,
科学领域:
- 生物医学工程
- 材料科学
- 皮肤病学
背景情况:
- 在牛皮的皮肤中,通过皮肤输送高分子量药物,如甲醇 (MTX) 具有挑战性.
- 牛皮的治疗通常需要有效的局部药物输送方法.
研究的目的:
- 开发一种可穿戴的离子体补丁,用于增强MTX的通过皮肤传递.
- 在牛皮小鼠模型中评估MTX补丁的疗效和安全性.
主要方法:
- 用于MTX加载和控制释放的聚烯涂层纸质基板的制造.
- 应用 -1.2 V 电位用于离子解离药物输送.
- 通过皮肤模型评估MTX透.
- 治疗疗效和全身毒性的评估,在一种因伊米基莫德 (IMQ) 诱导的牛皮的小鼠模型中进行.
主要成果:
- 离子化贴片实现了有效的MTX释放和透 (2小时内20.8±0.4μg/cm2),并尽量减少被动泄漏.
- 在小鼠模型中,该贴片显著缓解了牛皮的症状.
- 组织学分析证实了治疗效果和良好的生物相容性,系统性毒性较低.
结论:
- 开发的基于纸张的离子体治疗平台是精确且对患者友好的治疗策略.
- 这项技术有可能用于治疗需要通过皮肤输送药物的其他皮肤疾病.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233


